THIS SUMMARY OF CELL TRANSPLANT TRIALS, (cord, bone marrow,peripheral blood, and iPS) is surprisingly sparse, given the many thousands of patients that have been treated worldwide. Autologous treatments (the patient’s own cells) are considered the lowest adverse risk, and often the diseases have no other options. Most centers advertise their own outcome data separately.
http://bloodjournal.hematologylibrary.org/content/122/4/491.full
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022